ArticleThe Journal of antimicrobial chemotherapy2021
Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections.
Article in The Journal of antimicrobial chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 108 citations in OpenAlex.
- Pharmacokinetics and Safety of Ceftazidime-Avibactam in Neonates and Young Infants: A Phase 2a, Multicenter Prospective Trial.Journal of the Pediatric Infectious Diseases Society · 2025Trial
- Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study.Open forum infectious diseases · 2025Trial
- Use of Ceftazidime-Avibactam in a Late-Preterm Newborn with Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- High burden of blaBMC microbiology · 2026Article
- Phenotypic Resistance Profiles, Biofilm Formation, and In Vitro Carbapenem-Sparing Antimicrobial Activity in Enterobacterales Causing Acute Pyelonephritis.Microorganisms · 2026Article
- Interpretive agreement of susceptibility between broth microdilution and disk diffusion methods for cefiderocol, using criteria from the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing, and the Food and Drug Administration.Journal of clinical microbiology · 2026Article
- Epidemiology of ESBL-Producing, Carbapenem-Resistant, and Carbapenemase-Producing Enterobacterales in Southern Africa.Antibiotics (Basel, Switzerland) · 2026Review
- Anti-Infective-Associated AKI: A Narrative Review of the Epidemiology, Mechanisms, Risk Factors, Biomarkers, Clinical Course, Monitoring, Prevention, and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli.Microbiology spectrum · 2025Article
- Carbapenem-Resistant Enterobacteriaceae (CRE) in Children with Cancer: The Impact of Rapid Diagnostics and Targeted Colonization Strategies on Improving Outcomes.Microorganisms · 2025Article
- Microbial Multidrug-Resistant Organism (MDRO) Mapping of Intensive Care Unit Infections.Medicina (Kaunas, Lithuania) · 2025Observational
- Historical Overview of the Evolution of Multidrug-Resistant Gram-Negative Infections in Tunisia from 1999 to 2019.Antibiotics (Basel, Switzerland) · 2025Article
- Novel p-Hydroxybenzoic Acid Derivative Isolated fromAntibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial use regulations are associated with increased susceptibility among bovineOne health (Amsterdam, Netherlands) · 2025Article
- Recent Developments in Penem Antibiotics: Structural and Therapeutic Perspectives.Molecules (Basel, Switzerland) · 2025Review
- Antibiotic Resistance and Mortality in ICU Patients: A Retrospective Analysis of First Culture Growth Results.Antibiotics (Basel, Switzerland) · 2025Article
- Impact of high frequency electromagnetic radiation on bacterial survival and antibiotic activity in exposed bacteria.Scientific reports · 2025Article
- Proteome-wide identification of druggable targets and inhibitors for multidrug-resistantHeliyon · 2025Article
- Role of Divalent Ions in Membrane Models of Polymyxin-Sensitive and Resistant Gram-Negative Bacteria.Journal of chemical information and modeling · 2025Article
- Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial resistance is a serious threat to human health worldwide. Among the World Health Organisation's list of priority resistant bacteria, three are listed as critical-the highest level of concern-and all three are Gram-negative. Gram-negative resistance has spread worldwide via a variety of mechanisms, the most problematic being via AmpC enzymes, extended-spectrum β-lactamases, and carbapenemases. A combination of older drugs, many with high levels of toxicity, and newer agents are being used to combat multidrug resistance, with varying degrees of success. This review discusses the current treatments for multidrug-resistant Gram-negative bacteria, including new agents, older compounds, and new combinations of both, and some new treatment targets that are currently under investigation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.